Genzyme, a Sanofi Company Company Profile

23:57 EDT 21st June 2018 | BioPortfolio

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at

News Articles [853 Associated News Articles listed on BioPortfolio]

Growing up Genzyme

Sanofi’s proposed acquisition of Bioverativ solidifies Genzyme as Sanofi’s growth engine.

Sanofi turns down option to develop lumasiran

Alnylam Pharmaceuticals says that Sanofi Genzyme, the biotech unit of French pharma major Sanofi has…

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 19022018] Prices from USD $350

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investments report inclu...

Operations reshuffle behind job cuts at Sanofi Genzyme

Outsourcing and operational changes at the Allston Landing facility influenced Sanofiâs decision to layoff workers in Massachusetts, US.

Sanofi Quarterly Sales Sluggish with Focus on Integrating Bioverativ and Ablynx

Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology...

Sanofi Gains Rights to Hemophilia Drug in Restructured Deal With Alnylam

All other terms of the 2014 Alnylam-Sanofi Genzyme alliance remain unchanged.

Sanofi passes on Alnylam's breakthrough therapy

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal. Sanofi, and its rare disease arm Genzyme, has opted out of ...

Sanofi Aktie: Gewinn mehr als verdoppelt!

Liebe Leser, Sanofi hat in den ersten 9 Monaten von guten Geschäften mit Impfstoffen sowie mit Medikamenten gegen Multiple Sklerose und gegen seltene Krankheiten der Tochter Genzyme profitiert. Ins.....

PubMed Articles [33 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

C-621/15 - W And Others v Sanofi Pasteur: An Example of Judicial Distortion and Indifference to Science.

This case commentary examines the CJEU's recent decision in C-621/15 W and Others v Sanofi Pasteur MSD SNC [2017] ECR I. This commentary critically examines the decision through the lens of the cultur...

Bacteria and fungi in day-old turkeys vary among companies, collection periods, and breeder flocks.

Microbial colonization of the intestinal tract of commercial poultry is highly variable, likely due to the fact that poults and chicks are hatched and raised without exposure to adult birds and their ...

Crimean Thornapple Depicted by Liebig's Extract of Meat Company.

What do company health insurance plans provide?

Company health insurance plans are a voluntary employer benefit and an increasingly important part of company pension and benefits systems. They enable employers to invest in the health of their emplo...

Clinical Trials [161 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)

The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approve...

Companies [1493 Associated Companies listed on BioPortfolio]

Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...

Sanofi and Warp Drive Bio

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human va...


SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide: D...

Sanofi Genzyme

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, prov...

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

More Information about "Genzyme, a Sanofi Company" on BioPortfolio

We have published hundreds of Genzyme, a Sanofi Company news stories on BioPortfolio along with dozens of Genzyme, a Sanofi Company Clinical Trials and PubMed Articles about Genzyme, a Sanofi Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genzyme, a Sanofi Company Companies in our database. You can also find out about relevant Genzyme, a Sanofi Company Drugs and Medications on this site too.

Quick Search


Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record